众生药业:公司正在积极推进RAY1225注射液的III期临床试验

中金财经
May 14

  证券之星消息,众生药业(002317)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问:公司的RAY1225创新三期试验进展如何?减重版三期试验什么时间全部结束?读取数据大概需要多长时间?众生药业回复:您好!公司正在积极推进RAY1225注射液的III期临床试验,有关创新药的进展情况请以公司公告为准。谢谢!为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10